Featured Press Releases

Cellino Launches the U.S.’s First Nebula-Powered iPSC Foundry for Scalable Autologous Biomanufacturing

Cellino Launches the U.S.’s First Nebula-Powered iPSC Foundry for Scalable Autologous Biomanufacturing

Dupixent® outperformed Xolair® in treating CRSwNP with asthma in the first Phase 4 head-to-head trial

Dupixent® outperformed Xolair® in treating CRSwNP with asthma in the first Phase 4 head-to-head trial

  • 16 Jun 2025

Regeneron Pharmaceuticals, Inc. and Sanofi today presented positive results from the EVEREST Phase 4...

Vertex Shares New Data on ALYFTREK® Benefits and Sweat Chloride Reduction

Vertex Shares New Data on ALYFTREK® Benefits and Sweat Chloride Reduction

Mediar Therapeutics launches a second clinical program targeting fibrosis with novel first-in-class antibodies

Mediar Therapeutics launches a second clinical program targeting fibrosis with novel first-in-class antibodies

Thermo Fisher Scientific Unveils Integrated Platform to Enhance Biologics Development

Thermo Fisher Scientific Unveils Integrated Platform to Enhance Biologics Development

New Study Suggests 5-MTHF as Effective Alternative to Folic Acid in Later Pregnancy

New Study Suggests 5-MTHF as Effective Alternative to Folic Acid in Later Pregnancy

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

  • Aspera Biomedicines Inc.
  • 18 May 2026
Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

  • Galvanize Therapeutics, Inc.
  • 18 May 2026
Peter Menziuso named EVP and President of BD Interventional

Peter Menziuso named EVP and President of BD Interventional

  • BD
  • 18 May 2026
A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

  • Ferring Pharmaceuticals
  • 17 May 2026
Biohack skin longevity with Futurecode Booster

Biohack skin longevity with Futurecode Booster

  • Dermalogica
  • 16 May 2026
ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

  • AstraZeneca
  • 15 May 2026
The Digital Pharma Advances Conference 2026

Most Popular
May   2026
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.